Merck Beats Q1 Estimates on Strong Keytruda Sales Despite Acquisition-Related Loss

Merck's first-quarter results surpassed expectations thanks to its blockbuster cancer drug, Keytruda, despite a reported loss caused by a one-time acquisition charge.

Keytruda's success stems from recent approvals for new uses, like early-stage bladder cancer, and a new, more convenient subcutaneous injection.

The company faces future headwinds from upcoming U.S. drug price negotiations and continued weakness in its Gardasil vaccine sales in China.

Merck's latest earnings report might seem confusing at first glance, showing a loss, but the underlying business performance is actually quite strong.

The reported loss is not from poor sales, but from a large, one-time $9.0 billion research and development (R&D) charge. This was an expected accounting move that Merck had told investors about after acquiring a company called Cidara Therapeutics. If you look past this item, which financial analysts often do by looking at 'non-GAAP' earnings, the company's operational results beat expectations. Revenue reached $16.29 billion, surpassing the $15.82 billion consensus estimate.

The star of the show is Keytruda, Merck's leading cancer drug, which brought in $8.0 billion in revenue, well ahead of forecasts. This powerful performance is happening for a couple of key reasons. First, Keytruda is being approved for use in earlier stages of cancer treatment, specifically for bladder cancer. This expands its market, allowing more patients to receive the drug sooner in their treatment journey. Second, the recent approval of a subcutaneous (SC) version of Keytruda is a significant development. Instead of a lengthy IV infusion at a hospital, patients can receive a quick injection under the skin. This improves convenience for patients and efficiency for clinics, helping to boost sales volume.

However, it's not all smooth sailing. Merck is facing challenges with its Gardasil vaccine in China, where sales have been weak due to inventory issues and lower demand. While Keytruda's impressive growth is currently offsetting this headwind, it remains a point of concern for the company's overall portfolio balance.

A larger challenge looms on the horizon: the Inflation Reduction Act (IRA) in the United States. Starting in 2028, the U.S. government will have the power to negotiate the price of top-selling drugs like Keytruda. This will almost certainly lead to lower prices and reduced revenue from its biggest market. This makes Merck's current efforts to maximize Keytruda's sales volume through new approvals and the more convenient SC version even more critical. In short, Merck's Q1 results show a company successfully expanding the reach of its most important product to prepare for future pricing pressures. The headline loss is simply accounting noise, while the real story is the operational strength driven by Keytruda.

GAAP/non-GAAP: GAAP (Generally Accepted Accounting Principles) is the standard accounting rulebook. Non-GAAP figures adjust these standard numbers to exclude one-time or non-operational items, like a large acquisition charge, to give a clearer view of core business performance.
Subcutaneous (SC) injection: An injection administered into the fatty tissue just beneath the skin. It is often faster and more convenient than an intravenous (IV) infusion, which delivers medication directly into a vein.
Inflation Reduction Act (IRA): A U.S. law passed in 2022 that includes provisions allowing the government's Medicare program to negotiate prices for certain high-cost prescription drugs.

Merck Beats Q1 Estimates on Strong Keytruda Sales Despite Acquisition-Related Loss

Merck's first-quarter results surpassed expectations thanks to its blockbuster cancer drug, Keytruda, despite a reported loss caused by a one-time acquisition charge.

Keytruda's success stems from recent approvals for new uses, like early-stage bladder cancer, and a new, more convenient subcutaneous injection.

The company faces future headwinds from upcoming U.S. drug price negotiations and continued weakness in its Gardasil vaccine sales in China.

Merck's latest earnings report might seem confusing at first glance, showing a loss, but the underlying business performance is actually quite strong.

GAAP/non-GAAP: GAAP (Generally Accepted Accounting Principles) is the standard accounting rulebook. Non-GAAP figures adjust these standard numbers to exclude one-time or non-operational items, like a large acquisition charge, to give a clearer view of core business performance.
Subcutaneous (SC) injection: An injection administered into the fatty tissue just beneath the skin. It is often faster and more convenient than an intravenous (IV) infusion, which delivers medication directly into a vein.
Inflation Reduction Act (IRA): A U.S. law passed in 2022 that includes provisions allowing the government's Medicare program to negotiate prices for certain high-cost prescription drugs.